The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Non-alcoholic fatty liver disease and diabetes
Open accessAbstract
Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM) are common conditions that regularly co-exist and can act synergistically to drive adverse outcomes. The presence of both NAFLD and T2DM increases the likelihood of the development of complications of diabetes (including both macro- and micro- vascular complications) as well as augmenting the risk of more severe NAFLD, including cirrhosis, hepatocellular carcinoma and death. The mainstay of NAFLD management is currently to reduce modifiable metabolic risk. Achieving good glycaemic control and optimising weight loss are pivotal to restricting disease progression. Once cirrhosis has developed, it is necessary to screen for complications and minimise the risk of hepatic decompensation. Therapeutic disease modifying options for patients with NAFLD are currently limited. When diabetes and NAFLD co-exist, there are published data that can help inform the clinician as to the most appropriate oral hypoglycaemic agent or injectable therapy that may improve NAFLD, however most of these data are drawn from observations in retrospective series and there is a paucity of well-designed randomised double blind placebo controlled studies with gold-standard end-points. Furthermore, given the heterogeneity of inclusion criteria and primary outcomes, as well as duration of follow-up, it is difficult to draw robust conclusions that are applicable across the entire spectrum of NAFLD and diabetes. In this review, we have summarised and critically evaluated the available data, with the aim of helping to inform the reader as to the most pertinent issues when managing patients with co-existent NAFLD and T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2739 · Cited by 200
RetractedRole of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 6×
“DNL, the process whereby carbohydrates are converted to lipid, also contributes to lipid accumulation within the liver.”
BackgroundInfluentialSteatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Calamita, E., Schmid, M., Kunz, M., Ndebele-Murisa, M. R., Magadza, C. H. D., Nyambe, I., & Wehrli, B. (2019) · Figshare · doi:10.26181/6153922fe919c · Cited by 4,222
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“GLP-1 is an insulin mimetic but also has many important extra-pancreatic effects including on satiety and increasing insulin sensitivity [106].”
BackgroundDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 2×
“[95] Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al.”
BackgroundVilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
McPherson, S., Hardy, T., Henderson, E., Burt, A. D., Day, C. P., & Anstee, Q. M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.034 · Cited by 1,060
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., Day, C., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc06-2247 · Cited by 992
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Adams, L. A., Sanderson, S., Lindor, K. D., & Angulo, P. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.012 · Cited by 911
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Cusi, K. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 911
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867 · cited 2×
“reduction in fat mass rather than osmotic diuresis [121].”
BackgroundPathogenesis of non-alcoholic fatty liver disease
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2010) · QJM · doi:10.1093/qjmed/hcp158 · Cited by 741
Self-citationAithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721
Sunny, N. E., Parks, E. J., Browning, J. D., & Burgess, S. C. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.004 · Cited by 672
Musso, G., Cassader, M., Rosina, F., & Gambino, R. (2012) · Diabetologia · doi:10.1007/s00125-011-2446-4 · Cited by 661
Wong, V. W.-S., Wong, G. L.-H., Choi, P. C.-L., Chan, A. W.-H., Li, M. K.-P., Chan, H.-Y., Chim, A. M.-L., Yu, J., Sung, J. J.-Y., & Chan, H. L.-Y. (2010) · Gut · doi:10.1136/gut.2009.205088 · Cited by 648
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625
Targher, G., Bertolini, L., Rodella, S., Tessari, R., Zenari, L., Lippi, G., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc07-0349 · Cited by 579
Ding, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557 · cited 2×
“GLP-1 analogue therapy improves hepatic steatosis [108] and steatohepatitis [109] in ob/ob mice as well as wild type”
BackgroundGupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532
Laferrère, B., Heshka, S., Wang, K., Khan, Y., McGinty, J., Teixeira, J., Hart, A. B., & Olivan, B. (2007) · Diabetes Care · doi:10.2337/dc06-1549 · Cited by 532
Tiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2169 · Cited by 524
Harnois, D. (2009) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(09)79298-0 · Cited by 505
Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1966 · Cited by 503 · cited 2×
“This is an op with diabetes [1,2] whilst the prevalence of biopsy proven NASH (non-alcoholic steatohepatitis) in asymptomatic type 2 diabetics with normal liver function tests (LFTs) was 20% [3].”
BackgroundFrom the metabolic syndrome to NAFLD or vice versa?
Vanni, E., Bugianesi, E., Kotronen, A., De Minicis, S., Yki-Järvinen, H., & Svegliati-Baroni, G. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.01.016 · Cited by 497
Schwarz, J.-M., Linfoot, P., Dare, D., & Aghajanian, K. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.1.43 · Cited by 496
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 2×
“[111] Körner M, Stöckli M, Waser B, Reubi JC.”
BackgroundGlucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456
Self-citationWang, C., Wang, X., Gong, G., Ben, Q., Qiu, W., Chen, Y., Li, G., & Wang, L. (2012) · International Journal of Cancer · doi:10.1002/ijc.26165 · Cited by 449
Nonalcoholic fatty liver disease in patients with type 2 diabetes
Younossi, Z. M., Gramlich, T., Matteoni, C. A., Boparai, N., & McCullough, A. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00014-x · Cited by 443
Ryysy, L., Häkkinen, A. M., Goto, T., Vehkavaara, S., Westerbacka, J., Halavaara, J., & Yki-Järvinen, H. (2000) · Diabetes · doi:10.2337/diabetes.49.5.749 · Cited by 431
Adams, L. A., Waters, O. R., Knuiman, M. W., Elliott, R. R., & Olynyk, J. K. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.67 · Cited by 413
Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study.
de Marco, R., Locatelli, F., Zoppini, G., Verlato, G., Bonora, E., & Muggeo, M. (1999) · Diabetes Care · doi:10.2337/diacare.22.5.756 · Cited by 405
Chen, H.-P., Shieh, J.-J., Chang, C.-C., Chen, T.-T., Lin, J.-T., Wu, M.-S., Lin, J.-H., & Wu, C.-Y. (2013) · Gut · doi:10.1136/gutjnl-2011-301708 · Cited by 392
Williamson, R. M., Price, J. F., Glancy, S., Perry, E., Nee, L. D., Hayes, P. C., Frier, B. M., Van Look, L. A. F., Johnston, G. I., Reynolds, R. M., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2229 · Cited by 391
Targher, G., Bertolini, L., Rodella, S., Zoppini, G., Lippi, G., Day, C., & Muggeo, M. (2008) · Diabetologia · doi:10.1007/s00125-007-0897-4 · Cited by 383
Courcoulas, A. P., Belle, S. H., Neiberg, R. H., Pierson, S. K., Eagleton, J. K., Kalarchian, M. A., DeLany, J. P., Lang, W., & Jakicic, J. M. (2015) · JAMA Surgery · doi:10.1001/jamasurg.2015.1534 · Cited by 376 · cited 2×
“[122] Courcoulas AP, Belle SH, Neiberg RH, Pierson SK, Eagleton JK, Kalarchian MA, et al.”
BackgroundNonalcoholic fatty liver disease and mitochondrial dysfunction
Wei, Y., Rector, R. S., Thyfault, J. P., & Ibdah, J. A. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.193 · Cited by 369
Ratziu, V., Charlotte, F., Bernhardt, C., Giral, P., Halbron, M., LeNaour, G., Hartmann-Heurtier, A., Bruckert, E., & Poynard, T. (2010) · Hepatology · doi:10.1002/hep.23270 · Cited by 366
Pettinelli, P., & Videla, L. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2129 · Cited by 351
Independent Predictors of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Hossain, N., Afendy, A., Stepanova, M., Nader, F., Srishord, M., Rafiq, N., Goodman, Z., & Younossi, Z. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.06.007 · Cited by 342
Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis
Ferslew, B. C., Xie, G., Johnston, C. K., Su, M., Stewart, P. W., Jia, W., Brouwer, K. L. R., & Sidney Barritt, A. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3776-8 · Cited by 335
Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
Ben-Shlomo, S., Zvibel, I., Shnell, M., Shlomai, A., Chepurko, E., Halpern, Z., Barzilai, N., Oren, R., & Fishman, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.032 · Cited by 328
du Plessis, J., van Pelt, J., Korf, H., Mathieu, C., van der Schueren, B., Lannoo, M., Oyen, T., Topal, B., Fetter, G., Nayler, S., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.044 · Cited by 325
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
Lewis, J. D., Habel, L. A., Quesenberry, C. P., Strom, B. L., Peng, T., Hedderson, M. M., Ehrlich, S. F., Mamtani, R., Bilker, W., Vaughn, D. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.7996 · Cited by 320
Singh, S., Singh, P. P., Singh, A. G., Murad, M. H., & Sanchez, W. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.5 · Cited by 320
Svegliati-Baroni, G., Ridolfi, F., Di Sario, A., Casini, A., Marucci, L., Gaggiotti, G., Orlandoni, P., Macarri, G., Perego, L., Benedetti, A., et al. (1999) · Hepatology · doi:10.1002/hep.510290632 · Cited by 320
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.05.014 · Cited by 310
Kantartzis, K., Peter, A., Machicao, F., Machann, J., Wagner, S., Königsrainer, I., Königsrainer, A., Schick, F., Fritsche, A., Häring, H.-U., et al. (2009) · Diabetes · doi:10.2337/db09-0279 · Cited by 303
Adams, L. A., Harmsen, S., St. Sauver, J. L., Charatcharoenwitthaya, P., Enders, F. B., Therneau, T., & Angulo, P. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.18 · Cited by 293
Trevaskis, J. L., Griffin, P. S., Wittmer, C., Neuschwander-Tetri, B. A., Brunt, E. M., Dolman, C. S., Erickson, M. R., Napora, J., Parkes, D. G., & Roth, J. D. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00476.2011 · Cited by 277 · cited 3×
“[109] Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, et al.”
BackgroundThe role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease
Polyzos, S. A., Kountouras, J., Zavos, C., & Tsiaousi, E. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01176.x · Cited by 277
Topping, D. L., & Mayes, P. A. (1972) · Biochemical Journal · doi:10.1042/bj1260295 · Cited by 275
Garcia-Monzón, C., Martín-Pérez, E., Iacono, O. L., Fernández-Bermejo, M., Majano, P. L., Apolinario, A., Larrañaga, E., & Moreno-Otero, R. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80301-3 · Cited by 265
Bower, G., Toma, T., Harling, L., Jiao, L. R., Efthimiou, E., Darzi, A., Athanasiou, T., & Ashrafian, H. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1691-x · Cited by 256
A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
Fernández-Miranda, C., Pérez-Carreras, M., Colina, F., López-Alonso, G., Vargas, C., & Solís-Herruzo, J. A. (2008) · Digestive and Liver Disease · doi:10.1016/j.dld.2007.10.002 · Cited by 256
Armstrong, M. J., Houlihan, D. D., Rowe, I. A., Clausen, W. H. O., Elbrønd, B., Gough, S. C. L., Tomlinson, J. W., & Newsome, P. N. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12149 · Cited by 250
Self-citationNonalcoholic Fatty Liver Disease Is a Risk Factor for Type 2 Diabetes in Middle-Aged Japanese Men
Shibata, M., Kihara, Y., Taguchi, M., Tashiro, M., & Otsuki, M. (2007) · Diabetes Care · doi:10.2337/dc07-0792 · Cited by 238
Sung, K.-C., Jeong, W.-S., Wild, S. H., & Byrne, C. D. (2012) · Diabetes Care · doi:10.2337/dc11-1853 · Cited by 218
Relationship of sitting time and physical activity with non-alcoholic fatty liver disease
Ryu, S., Chang, Y., Jung, H.-S., Yun, K. E., Kwon, M.-J., Choi, Y., Kim, C.-W., Cho, J., Suh, B.-S., Cho, Y. K., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.010 · Cited by 209
Hallsworth, K., Thoma, C., Hollingsworth, K. G., Cassidy, S., Anstee, Q. M., Day, C. P., & Trenell, M. I. (2015) · Clinical Science · doi:10.1042/cs20150308 · Cited by 201 · cited 2×
“week for 12 weeks has been shown to reduce hepatic steatosis measured with MRS [62].”
BackgroundKotronen, A., Juurinen, L., Hakkarainen, A., Westerbacka, J., Cornér, A., Bergholm, R., & Yki-Järvinen, H. (2008) · Diabetes Care · doi:10.2337/dc07-1463 · Cited by 196 · cited 2×
“Given the insidious nature of type 2 diabetes, it is not surprising that those with established diabetes have markedly more liver fat when compared to age, BMI and gender matched controls [28].”
BackgroundRoux‐en‐Y Gastric Bypass Improves Liver Histology in Patients with Non‐Alcoholic Fatty Liver Disease
Clark, J. M., Alkhuraishi, A. R. A., Solga, S. F., Alli, P., Diehl, A. M., & Magnuson, T. H. (2005) · Obesity Research · doi:10.1038/oby.2005.140 · Cited by 184
Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease
Souza-Mello, V. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i8.1012 · Cited by 182
Zhang, X., Harmsen, W. S., Mettler, T. A., Kim, W. R., Roberts, R. O., Therneau, T. M., Roberts, L. R., & Chaiteerakij, R. (2014) · Hepatology · doi:10.1002/hep.27199 · Cited by 181
Yamazaki, H., Tsuboya, T., Tsuji, K., Dohke, M., & Maguchi, H. (2015) · Diabetes Care · doi:10.2337/dc15-0140 · Cited by 172
Ford, R. J., Fullerton, M. D., Pinkosky, S. L., Day, E. A., Scott, J. W., Oakhill, J. S., Bujak, A. L., Smith, B. K., Crane, J. D., Blümer, R. M. E., et al. (2015) · Biochemical Journal · doi:10.1042/bj20150125 · Cited by 172
Penney, N. C., Kinross, J. K., Newton, R. C., & Purkayastha, S. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.115 · Cited by 159
Park, S. K., Seo, M. H., Shin, H. C., & Ryoo, J.-H. (2013) · Hepatology · doi:10.1002/hep.26183 · Cited by 158
Sharma, M., Mitnala, S., Vishnubhotla, R., Mukherjee, R., Reddy, D. N., & Rao, P. N. (2015) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2015.02.002 · Cited by 158
Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study
Group Study D.E.S.I.R., Balkau, B., Lange, C., Vol, S., Fumeron, F., & Bonnet, F. (2010) · BMC Gastroenterology · doi:10.1186/1471-230x-10-56 · Cited by 153
Gastrointestinal changes after bariatric surgery
Quercia, I., Dutia, R., Kotler, D. P., Belsley, S., & Laferrère, B. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.11.003 · Cited by 153
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease
Gramlich, T. L., Kleiner, D. E., McCullough, A. J., Matteoni, C. A., Boparai, N., & Younossi, Z. M. (2004) · Human Pathology · doi:10.1016/j.humpath.2003.09.018 · Cited by 151
Athyros, V. G., Τζιόμαλος, Κ., Katsiki, N., Doumas, M. N., Karagiannis, A. I., & Mikhailidis, D. P. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i22.6820 · Cited by 149
The future role of gut hormones in the treatment of obesity
Troke, R., Tan, T., & Bloom, S. R. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313506730 · Cited by 143
Juurinen, L., Tiikkainen, M., Häkkinen, A.-M., Hakkarainen, A., & Yki-Järvinen, H. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00133.2006 · Cited by 141 · cited 2×
“This finding corroborates observations fromprevious studies [65,66].”
Bae, J. C., Rhee, E., Lee, W., Park, S. E., Park, C., Oh, K. W., Park, S. W., & Kim, S. W. (2011) · Diabetes Care · doi:10.2337/dc10-1991 · Cited by 141
Kaji, K., Yoshiji, H., Ikenaka, Y., Noguchi, R., Aihara, Y., Douhara, A., Moriya, K., Kawaratani, H., Shirai, Y., Yoshii, J., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0783-4 · Cited by 139
Tang, A., RABASA-LHORET, R. P. R., Castel, H., Wartelle‐Bladou, C., Gilbert, G., Massicotte-Tisluck, K., Chartrand, G., Olivié, D., Julien, A., de Guise, J. A., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2548 · Cited by 139
Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes
Aubert, R. E., Herrera, V., Chen, W., Haffner, S. M., & Pendergrass, M. L. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01225.x · Cited by 135
Interrelationship between Fatty Liver and Insulin Resistance in the Development of Type 2 Diabetes
Sung, K., & Kim, S. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2190 · Cited by 135
Bae, J. C., Cho, Y. K., Lee, W., Seo, H. I., Rhee, E., Park, S. E., Park, C., Oh, K. W., Sung, K., & Kim, B. I. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2010.275 · Cited by 129
Effect of Vildagliptin on Hepatic Steatosis
Macauley, M., Hollingsworth, K. G., Smith, F. E., Thelwall, P. E., Al-Mrabeh, A. H., Schweizer, A., Foley, J. E., & Taylor, R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3794 · Cited by 128
Yamada, T., Fukatsu, M., Suzuki, S., Wada, T., Yoshida, T., & Joh, T. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.05998.x · Cited by 126
Dipeptidyl peptidase IV (DDP IV) in NASH patients
Balaban, Y. H., Korkusuz, P., Simsek, H., Gokcan, H., Gedikoglu, G., Pinar, A., Hascelik, G., Asan, E., Hamaloglu, E., & Tatar, G. (2007) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31905-2 · Cited by 125
Iwasaki, T., Yoneda, M., Inamori, M., Shirakawa, J., Higurashi, T., Maeda, S., Terauchi, Y., & Nakajima, A. (2011) · Hepatogastroenterology · doi:10.5754/hge11263 · Cited by 124
Scheen, A. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.978289 · Cited by 120
Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults
Kim, C., Park, J.-Y., Lee, K.-U., Kim, J. H., & Kim, H. ‐. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02410.x · Cited by 118
Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity
Kern, M., Klöting, N., Niessen, H. G., Thomas, L. H., Stiller, D., Mark, M., Klein, T., & Blüher, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038744 · Cited by 117
Zarrinpar, A., & Loomba, R. S. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12084 · Cited by 113
Hayashizaki, Y., Kurosaki, E., Takasu, T., Mitori, H., Yamazaki, S., Koide, K., & Takakura, S. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.009 · Cited by 112
Chen, T., Lin, C., Huang, P., & Wen, C. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06664.x · Cited by 107
The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes
Whalen, K., Miller, S. A., & Onge, E. S. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.03.004 · Cited by 103
Wong, V. W., Hui, A., Tsang, S. W., Chan, J. L.-Y., Wong, G. L., Chan, A. W. H., So, W., CHENG, A. Y. S., Tong, P. C. Y., Chan, F. K. L., et al. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03112.x · Cited by 96
Zelber‐Sagi, S., Lotan, R., Shibolet, O., Webb, M., Buch, A., Nitzan, D., Halpern, Z., Santo, E., & Oren, R. (2013) · Liver International · doi:10.1111/liv.12200 · Cited by 96
Yan, F., Wang, Q., Xu, C., Cao, M., Zhou, X., Wang, T., Yu, C., Jing, F., Chen, W., Gao, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099245 · Cited by 81
Association between the Fatty Liver Index and Risk of Type 2 Diabetes in the EPIC-Potsdam Study
Jäger, S., Jacobs, S., Kröger, J., Stefan, N., Fritsche, A., Weikert, C., Boeing, H., & Schulze, M. B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124749 · Cited by 70
Liver Fat Content and Hepatic Insulin Sensitivity in Overweight Patients With Type 1 Diabetes
Llauradó, G., Sevastianova, K., Sädevirta, S., Hakkarainen, A., Lundbom, N. M. I., Orho‐Melander, M., Groop, P., Forsblom, C. M., & Yki‐Järvinen, H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3050 · Cited by 62
Thiazolidinediones and the liver in humans
Yki‐Järvinen, H. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283321d37 · Cited by 62
Choi, J. H., Rhee, E., Bae, J. C., Park, S. E., Park, C., Cho, Y. K., Oh, K. W., Park, S., & Lee, W. (2013) · Archives of Medical Research · doi:10.1016/j.arcmed.2013.01.007 · Cited by 60
Type 1 diabetes is not associated with an increased prevalence of hepatic steatosis
Petit, J., Pedro, L. N., Guiu, B., Duvillard, L., Bouillet, B., Jooste, V., Habchi, M., Crevisy, E., Fourmont, C., Buffier, P., et al. (2015) · Diabetic Medicine · doi:10.1111/dme.12805 · Cited by 58
Armstrong, M. J., Hazlehurst, J., Parker, R., Koushiappi, E., Mann, J. P., Khan, S., Philips, A., Chandler, L., Johnson, J. L., Round, M., et al. (2013) · QJM · doi:10.1093/qjmed/hct198 · Cited by 55
Self-citationEffect of insulin–metformin combination on hepatic steatosis in patients with type 2 diabetes
Lingvay, I., Raskin, P., & Szczepaniak, L. S. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2007.02.005 · Cited by 55
Williams, K., de Ribeiro, A. J. V., Prakoso, E., Veillard, A., Shackel, N. A., Brooks, B. A., Bu, Y., Cavanagh, E., Raleigh, J., McLennan, S. V., et al. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12237 · Cited by 52
Rapid Reversal of Liver Steatosis With Life Style Modification in Highly Motivated Liver Donors
Choudhary, N. S., Saraf, N., Saigal, S., Gautam, D., Lipi, L., Rastogi, A. N., Goja, S. K., Menon, P. B., Bhangui, P., Ramchandra, S. K., et al. (2015) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2015.04.002 · Cited by 49
Influence of gut bacteria on development and progression of non-alcoholic fatty liver disease
Abdul‐Hai, A., Abdallah, A., & Malnick, S. D. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i12.1679 · Cited by 44
Ming, J., Xu, S., Gao, B., Liu, G., Ji, Y., Yang, F., Jia, Y., Fang, Y., & Ji, Q. (2015) · Liver International · doi:10.1111/liv.12851 · Cited by 44
Prevalence and markers of advanced liver disease in type 2 diabetes
Williamson, R. M., Price, J. F., Hayes, P. C., Glancy, S., Frier, B. M., Johnston, G. I., Reynolds, R. M., Strachan, M. W. J., & on behalf of the Edinburgh Type 2 Diabetes Study Investigators (2011) · QJM · doi:10.1093/qjmed/hcr233 · Cited by 39
Belcher, G., & Schernthaner, G. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01595.x · Cited by 39
Gliclazide-induced acute hepatitis
Dourakis, S. P., Tzemanakis, E. N., Sinani, C., Kafiri, G., & Hadziyannis, S. J. (2000) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200012010-00021 · Cited by 36
Cole, A. J., Teigen, L. M., Jahansouz, C., Earthman, C. P., & Sibley, S. D. (2015) · Current Obesity Reports · doi:10.1007/s13679-015-0171-x · Cited by 35
Metformin does not improve survival in patients with hepatocellular carcinoma
Bhat, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i42.15750 · Cited by 35
Regnell, S. E., Peterson, P., Trinh, L., Broberg, P., Leander, P., Lernmark, Å., Månsson, S., & Larsson, H. E. (2015) · Metabolism · doi:10.1016/j.metabol.2015.04.002 · Cited by 35
Derosa, G., Bonaventura, A., Bianchi, L., Romano, D., Fogari, E., D’Angelo, A., & Maffioli, P. (2014) · Metabolism · doi:10.1016/j.metabol.2014.04.008 · Cited by 34
Arase, Y., Kawamura, Y., Seko, Y., Kobayashi, M., Suzuki, F., Suzuki, Y., Akuta, N., Kobayashi, M., Sezaki, H., Saito, S., et al. (2013) · Hepatology Research · doi:10.1111/hepr.12077 · Cited by 34
Hillenbrand, A., Kiebler, B., Schwab, C., Scheja, L., Xu, P., Henne‐Bruns, D., Wolf, A. M., & Knippschild, U. (2015) · BMC Research Notes · doi:10.1186/s13104-015-1224-7 · Cited by 31
Chon, C. W., Kim, B., Cho, Y. K., Sung, K., Bae, J. C., Kim, T. W., Won, H. S., & Joo, K. J. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.3.368 · Cited by 31
Impact of Weight-Loss Surgery and Diabetes Status on Serum ALT Levels
Xourafas, D., Ardestani, A., Ashley, S. W., & Tavakkoli, A. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0677-1 · Cited by 27
Dunn, M. A., Behari, J., Rogal, S. S., O’Connell, M. R., Furlan, A., Aghayev, A., Gümüş, S., Saul, M. I., & Bae, K. T. (2013) · Liver International · doi:10.1111/liv.12285 · Cited by 25
Metabolic surgery: A paradigm shift in type 2 diabetes management
Pappachan, J. M., & Viswanath, A. K. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i8.990 · Cited by 22
Fatty liver score and 15-year incidence of type 2 diabetes
Kotronen, A., Laaksonen, M. A., Heliövaara, M., Reunanen, A., Tuomilehto, J. O., Yki‐Järvinen, H., Peltonen, M., & Knekt, P. (2013) · Hepatology International · doi:10.1007/s12072-013-9430-7 · Cited by 16
Zammit, V. A. (2000) · Biochemical Society Transactions · doi:10.1042/bst0280103 · Cited by 13
Armstrong, M. J., Gaunt, P., Aithal, G. P., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30002-7 · Cited by 13
Diabetes Mellitus, Insulin, Sulfonylurea and Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease
BoonBee, G. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000410 · Cited by 11
Margariti, A., Kontogianni, M. D., Tileli, N., Georgoulis, M., Deutsch, M. J., Zafeiropoulou, R., TINIAKOS, D. G., Μanios, Y., Pectasides, D. G., & Papatheodoridis, G. (2015) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000381 · Cited by 11
Jun, D. W., Kim, H. J., Bae, J. H., et al. (2011) · Hepatogastroenterology · doi:10.5754/hge10729 · Cited by 7
Matsumoto, N., Arase, Y., Kawamura, Y., Ohmoto-Sekine, M., Amakawa, K., Ogawa, K., Tsuji, H., Dong, H. S., Hara, S., Akuta, N., et al. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.3437 · Cited by 7
Cited by
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235
Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627
“In patients with prediabetes or T2DM serial liver biopsies revealed progressive fibrosis [113].”
BackgroundHealth benefits of resveratrol: Evidence from clinical studies
Singh, A. P., Singh, R., Verma, S. S., Rai, V., Kaschula, C. H., Maiti, P., & Gupta, S. C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21565 · Cited by 523
Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0641 · Cited by 360
Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications
Chen, J., & Vitetta, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155214 · Cited by 352
Metadata
- Authors
- Hazlehurst, J. M., Woods, C., Marjot, T., Cobbold, J. F., & Tomlinson, J. W.
- Venue
- Metabolism
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 65
- Issue
- 8
- Pages
- 1096-1108
- ISSN
- 0026-0495 (ISSN-L)
- OpenAlex
- W2237544788
- Cited by
- 527
- References
- 136
- FWCI
- 37.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.